Novel neoantigen identification platform advances prospects of OTS vaccine for breast cancer
A novel platform that can identify tumour-specific alternative splicing (AS)–derived neoantigens with high confidence level could potentially overcome key stumbling blocks in cancer neoantigen vaccine development, according to Ms Bui Que Tran Nguyen of the Medical Genetics Institute, Ho Chi Minh City, Vietnam, who presented her team’s findings at ESMO TAT Asia 2026.